清细胞细胞癌中的临床实践和预后分子生物标志物:最新进展
Gianluca Aguiari1, Lucio Dell'atti2
1Department of Neuroscience and Rehabilitation, University of Ferrara, Ferrara, Italy; dsn@unife.it.
Anticancer research
|September 26, 2025
概括
清细胞细胞癌 (ccRCC) 是一种常见的癌症,结果各异. 确定预后生物标志物对于有效的风险分层和ccRCC患者的个性化治疗策略至关重要.
科学领域:
- 在瘤学瘤学.
- 尿道瘤学 尿道瘤学
- 分子病理学分子病理学
背景情况:
- 细胞癌 (RCC),特别是清细胞RCC (ccRCC),占泌尿病恶性瘤的很大一部分.
- 不调节的信号通路 (VHL/HIF,mTOR,p53) 和改变的细胞死亡过程是ccRCC的特征.
- 目前的第一线疗法 (免疫检查点抑制剂,氨酸激酶抑制剂) 提高了存活率,但由于异质性,转移性RCC (mRCC) 仍然具有挑战性.
研究的目的:
- 审查RCC的临床参数,手术方法和全身疗法.
- 讨论关于ccRCC患者风险分层的假定预后分子生物标志物.
- 突出生物标志物的重要性,以指导治疗决策和细胞还原性切除术.
主要方法:
- 对ccRCC的临床和分子方面的文献综述.
- 对ccRCC涉及的信号通路和生物过程的分析.
- 讨论生物标志物在患者管理和预后中的实用性.
主要成果:
- ccRCC表现出显著的分子和病理生理异质性,导致不同的患者结果.
- 许多生物标志物与VHL/HIF,ERK/MAPK,mTOR/Akt通路以及细胞死亡过程 (自,铁亡等) 相关. 在ccRCC.中被修改.
- 临床参数,手术选择和全身疗法是已建立的管理策略.
结论:
- 准确的预后生物标志物对于将ccRCC患者分为高风险和低风险组来分层至关重要.
- 将生物标志物研究转化为临床实践可以优化治疗选择并改善患者管理.
- 对分子驱动因素和生物标志物的进一步研究是必要的,以克服治疗转移性ccRCC的挑战.
更多相关视频
05:36Comparing Metastatic Clear Cell Renal Cell Carcinoma Model Established in Mouse Kidney and on Chicken Chorioallantoic Membrane
Published on: February 8, 2020
9.4K
06:38A Syngeneic Mouse Model of Metastatic Renal Cell Carcinoma for Quantitative and Longitudinal Assessment of Preclinical Therapies
Published on: April 12, 2017
14.1K
相关概念视频
Targeted Cancer Therapies
8.6K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
8.6K
Cancer Survival Analysis
648
Cancer survival analysis focuses on quantifying and interpreting the time from a key starting point, such as diagnosis or the initiation of treatment, to a specific endpoint, such as remission or death. This analysis provides critical insights into treatment effectiveness and factors that influence patient outcomes, helping to shape clinical decisions and guide prognostic evaluations. A cornerstone of oncology research, survival analysis tackles the challenges of skewed, non-normally...
648
Combination Therapies and Personalized Medicine
5.9K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
5.9K
Tumor Progression
7.2K
Tumor progression is a phenomenon where the pre-formed tumor acquires successive mutations to become clinically more aggressive and malignant. In the 1950s, Foulds first described the stepwise progression of cancer cells through successive stages.
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
7.2K
